Apo-J/Clusterin recombinant protein
CLI, AAG4, KUB1, SGP2, SGP-2, SP-40, TRPM2, , MGC24903, Clusterin, Apolipoprotein J, Apo-J
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P10909 |
---|---|
Calculated MW | 75-80 kDa |
Gene ID | 1191 |
---|---|
Gene Symbol | TRPM-2 |
Other Names | CLI, AAG4, KUB1, SGP2, SGP-2, SP-40, TRPM2, , MGC24903, Clusterin, Apolipoprotein J, Apo-J, Apolipoprotein, apolipoproteins, Aging-associated gene 4 protein, Complement cytolysis inhibitor, Complement-associated protein SP-40, 40, Ku70-binding protein 1, NA1/NA2, Testosterone-repressed prostate message 2 |
Source | Plasma |
Assay&Purity | SDS-PAGE; ≥95% |
Assay2&Purity2 | HPLC; ≥95% |
Recombinant | No |
Target/Specificity | ApoJ/Clusterin |
Application Notes | Reconstitute in dH₂O to a working volume of 0.5 mg/ml and let the lyophilized pellet dissolve completely. |
Format | Lyophilized protein |
Storage | -20°C; Sterile filtered and lyophilized from PBS, pH 7.5. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Apoliprotein J (APO-J), also named Clusterin, is a 75-80 kD disulfide-linked heterodimeric protein. The precursor polypeptide chain is cleaved proteolytically to remove the 22-mer secretory signal peptide and subsequently between residues 227/228 to generate the a and b chains. These are assembled in anti-parallel to give a heterodimeric molecule in which the cysteine-rich centers are linked by five disulfide bridges and are flanked by two predicted coiled-coil a-helices and three predicted amphipathic a-helices. Clusterin is up- or down regulated on the mRNA or protein level in many pathological and clinically relevant situations including cancer, organ regeneration, infection, Alzheimer disease, retinitis pigmentosa, myocardial infarction, renal tubular damage, autoimmunity and others.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.